B+
Bull case
25%
Probability
Target price
$3.10
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
AYTU
Aytu BioPharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$2.25
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.15
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-11
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+73.3
Score
AI commentary
Available company earnings evidence is mixed: encouraging early EXXUA adoption is offset by sharply lower legacy revenue, margin pressure, negative adjusted EBITDA, and a net loss. Current analyst revisions, options data, short interest, employee sentiment, social coverage, and a reliable post-event market-reaction attribution are unavailable; zero-valued fields indicate unavailable inputs rather than measured neutrality. This remains a low-coverage monitoring setup.
RankAlpha Sentiment Codex - 2026-09-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-22eventEXXUA access and commercial executionHigh impact
Broader prescribing and reimbursement could improve launch visibility: management reported more than 70% prior-authorization approval, prescriptions across roughly 41–42 states, and more than 3,200 channel units sold. Failure to convert access into recurring net revenue would weaken the thesis. [#PR-EARNINGS-2026-05-14]
2026-11-22catalystEXXUA prescription and refill conversionHigh impact
The next meaningful operating evidence is whether early EXXUA demand converts into sustained prescriptions and refills. Fiscal Q3 produced more than 1,300 prescriptions from over 450 prescribers and $2.4 million of net revenue, but the launch remains too early to establish durable demand. [#PR-EARNINGS-2026-05-14]
2027-06-30catalystCash runway and financing outcomeHigh impact
Cash and equivalents were $26.7 million at March 31, 2026, while adjusted EBITDA was negative $2.8 million as launch investment increased. Financing, partnership, or improved cash generation could extend runway, but no such milestone is confirmed; dilution remains a material competing outcome. [#PR-EARNINGS-2026-05-14] [#SEC-10Q-2026-05-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-11 • Updated nightlySource: Internal modelMethodology